Agonist-Biased Signaling at the sst2A Receptor: The Multi-Somatostatin Analogs KE108 and SOM230 Activate and Antagonize Distinct Signaling Pathways

Somatostatin analogs that activate the somatostatin subtype 2A (sst2A) receptor are used to treat neuroendocrine cancers because they inhibit tumor secretion and growth. Recently, new analogs capable of activating multiple somatostatin receptor subtypes have been developed to increase tumor responsi...

Полное описание

Сохранить в:
Библиографические подробности
Главные авторы: Cescato, Renzo, Loesch, Kimberly A., Waser, Beatrice, Mäcke, Helmut R., Rivier, Jean E., Reubi, Jean Claude, Schonbrunn, Agnes
Формат: Artigo
Язык:Inglês
Опубликовано: The Endocrine Society 2010
Предметы:
Article
Online-ссылка:https://ncbi.nlm.nih.gov/pmc/articles/PMC2802896/
https://ncbi.nlm.nih.gov/pubmed/19910453
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1210/me.2009-0321
Метки: Добавить метку
Нет меток, Требуется 1-ая метка записи!

Схожие документы